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While administration of medical aerosols with heliox and positive airway pressure are both
used clinically to improve aerosol delivery, few studies have differentiated their separate roles
in treatment of asthmatics. The aim of this randomized, double blinded study is to differen-
tiate the effect of heliox and oxygen with and without positive expiratory pressure (PEP),
on delivery of radiotagged inhaled bronchodilators on pulmonary function and deposition in
asthmatics. 32 patients between 18 and 65 years of age diagnosed with stable moderate to se-
vere asthma were randomly assigned into four groups: (1) Heliox þ PEP (n Z 6), (2)
Oxygen þ PEP (n Z 6), (3) Heliox (n Z 11) and (4) Oxygen without PEP (n Z 9). Each group
received 1 mg of fenoterol and 2 mg of ipratropium bromide combined with 25 mCiructive pulmonary disease; CPAP, continuous positive airway pressure; DBP, systolic blood pressure;
taacetic acid technetium-99m; EPAP, expiratory positive airway pressure; FEV1, forced expiratory
d vital capacity; IC, inspiratory capacity; IPPB, intermittent positive pressure breathing; HR, heart
; PEEP, positive end expiratory pressure; PEEPi, intrinsic positive end expiratory pressure; PEF, peak
ROIs, regions of interest; SBP, diastolic blood pressure; SpO2, peripheral oxygen saturation.
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Heliox and PEP: evaluation of lung function and deposition 1179(955 Mbq) of Technetium-99m and 0.9% saline to a total dose volume of 3 mL placed in a
Venticis II nebulizer attached to a closed, valved mask with PEP of 0 or 10 cm H2O. Both
gas type and PEP level were blinded to the investigators. Images were acquired with a
single-head scintillation camera with the longitudinal and transverse division of the right lung
as regions of interest (ROIs). While all groups responded to bronchodilators, only group 1
showed increase in FEV1%predicted and IC compared to the other groups (p < 0.04). When eval-
uating the ROI in the vertical gradient we observed higher deposition in the middle and lower
third in groups 1 (pZ 0.02) and 2 (pZ 0.01) compared to group 3. In the horizontal gradient, a
higher deposition in the central region in groups 1 (p Z 0.03) and 2 (p Z 0.02) compared to
group 3 and intermediate region of group 2 compared to group 3. We conclude that aerosol
deposition was higher in groups with PEP independent of gas used, while bronchodilator
response with Heliox þ PEP improved FEV1 % and IC compared to administration with Oxygen,
Oxygen with PEP and Heliox alone. Trial registration NCT01268462.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
In moderate to severe asthmatic subjects, airway obstruc-
tion has been associated with heterogeneous distribution of
inhaled drugs with preferential deposition in central air-
ways and less compromised areas, resulting in lower drug
effectiveness.1,2
Heliox-driven aerosol drug administration has been
increasingly used in recent years to transport aerosols
deeper into the central and peripheral airways during se-
vere airway obstruction with greater efficiency than air or
oxygen, resulting in more homogenous deposition of aero-
solized medications with potentially greater clinical
response to bronchodilators.3e6
Although heliox-driven aerosol delivery of short acting
bronchodilators has been reported to elicit better bron-
chodilator response compared to administration with air or
oxygen, the results remain mixed across investigators. The
application of positive pressure to the airway during aerosol
administration has been associated with better response to
short acting bronchodilators than administration with
ambient pressures. Application of positive expiratory
pressure (PEP) with fixed orifice resistors, expiratory posi-
tive airway pressure (EPAP) with spring loaded threshold
resistors, high frequency oscillators with weighted ball or
spring loaded resistors and continuous positive airway
pressure (CPAP) have been reported to improve clinical
response with bronchodilator administration.7e10
Several studies3e19 have focused on ways to optimize
aerosol therapy for moderate to severe asthmatics through
the combination of positive airway pressure and reduced
density gas mixtures with nebulization. Positive expiratory
pressure (PEP), has been shown to promote dilation of
airways and decrease pulmonary resistance, while
improving response to inhaled bronchodilators. Mixtures of
helium with oxygen (heliox) have been shown to increase
peripheral delivery of aerosol during nebulization.2e19
Despite the demonstrated benefits of applying external
positive airway pressure and the use of heliox gas mixture
during nebulization, few randomized controlled studies
have evaluated the association between these two vari-
ables in treatment of asthmatics. The aim of this study is to
evaluate the influence of heliox and PEP as independentvariables during administration of radiotagged bronchodi-
lator aerosols on both pulmonary function and pulmonary
deposition in stable moderate to severe asthmatics.
Methods
Sample
The sample size was calculated based on a pilot study with
five patients in each group, totaling 20 patients. G. Power
Software 3.1 was used, considering a Z 0.05 and
1  b Z 0.80. Sample size calculation was based on the
percentage of predicted forced expiratory volume in the
first second (FEV1), as it best characterizes the degree of
airway obstruction. The protocol was approved by the
Human Research Ethics Committee (protocol no.437/2008),
according to resolution 196/96, and all study patients gave
their informed written consent.
Inclusion criteria were patients with clinical diagnosis of
persistent moderate to severe asthma, with percent of
predicted FEV1 from 60 to 80% or severe asthma with pre-
dicted FEV1 <60% for more than one year.
20 All patients
received combination therapy with bronchodilators and
corticosteroids long term (Formoterol e 12 mcg and Bude-
sonide e 400 mcg) and they are instructed to discontinue
medication 24 h prior to the study.
Excluded from the study were patients: unable to under-
stand or perform the spirometric maneuver or who failed to
maintain proper positioning to obtain scintigraphic images;
those with a history of smoking in the last three years, com-
bined with a consumption of more than 100 cigarettes per
year orwhohad smoked for at least 10 years; otherpulmonary
comorbidities such as chronic obstructive pulmonary disease
(COPD), bronchiectasis and tuberculosis sequelae, pregnancy
and any contraindication to the use of PEP,21 such as active
hemoptysis, acute sinusitis, facial surgery, oral, cranial or
facial trauma, nosebleed, esophageal surgery and nausea.
Study design
In this double-blind study, patients were randomly allo-
cated into four groups according to the type of propellant
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Heliox þ PEP (Group 1), Oxygen þ PEP (Group 2), Heliox
(Group 3) and Oxygen (Group 4). Simple randomization was
used in a draw where each patient had the same chance to
participate in any of the four groups (Figure 1). The gas
used was blinded by covering the cylinders and asking the
subjects not to talk during administration. The level of PEP
was blinded by using an identical valve without resistance
for patients in Groups 3 and 4.
Clinical evaluation
Initially, all patients underwent clinical evaluation con-
sisting of an anamnesis and measurement of cardiopulmo-
nary parameters such as respiratory rate (RR), peripheral
oxygen saturation (SpO2) measured by pulse oximetry (MD
300 D Beijing, China); heart rate (HR), systolic blood pres-
sure (SBP), diastolic blood pressure (DBP) obtained using
Welch Allyn DS 44-11 CB, USA; inspiratory capacity (IC);
spirometric parameters (portable MicroLoop spirometer,
Cardinal Health, digital volume transducer, England). All
parameters reassessed following scintigraphy.
Spirometry
To obtain spirometric values, patients were asked to
perform FEV1, peak expiratory flow (PEF) and forced vital
capacity (FVC) were analyzed, calculating the predicted
percentage FEV1 in accordance with the American Thoracic
Society.22 For IC, the patient was instructed to inspire to
total lung capacity and then to return to normal breathing,
and the mean of two largest ICs of at least three acceptable
tests were used, and had to agree within 5% or 60 mL.23
Lung inhalation scintigraphy
Diethylenetriaminepentaacetic acid was labeled with
925 Mbq (25 mCi) Technetium-99m (DTPA e Tc99m),and
combined with 1 mg of fenoterol bromide and 2 mg of
ipratropium using 0.9% saline solution to a total dose vol-
ume of 3 mL.Figure 1 FlA non-invasive delivery system was used that consists of
a closed, nontoxic orofacial mask (Vital signs e West Sus-
sex, UK) with two unidirectional valves e inspiratory and
expiratory branch e connected to the nebulizer for radio-
isotopes Venticis II Medical device, class II, CE 0459
(Ventibox/CIS Bio International, France). PEEP of 0 or 10 cm
H2O administered with a valve (Vital Signs, Toyota, NY),
attached to the expiratory port. The nebulizer was fed by a
flow of 8 L/min oxygen for the oxygen group and 11 L/min
of heliox as established by Hess et al.24The mask was sealed
to the patient’s face to prevent leaks and maintain proper
PEP (Figure 2). When driven by heliox, flow was adjusted to
the suitable flow for the gas mixture (White Martins).25
Inhalation was administered with subjects in an upright
sitting position over 9 min. Patients were previously advised
to breathe slowly and deeply through the mouth, making
one inspiratory pause for 3 s. After inhalation, patients
were instructed to rinse their mouth and drink water to
clear their throat and esophagus of radioaerosol deposited
in these regions. Subjects were advised to remain silent
during and for 2 min after administration of aerosol, since
heliox modifies voice timbre temporarily.19
At the end of inhalation, images were obtained with a
single-head scintillation camera (STARCAM 3200 AC/T GE
Medical Systems e UK), and stored in a 256  256 pixel
matrix. Patients were placed in the supine position and
instructed not to move during the imaging process. The
images were obtained over 5 min. For analysis of pulmonary
deposition, the division was held in the right lung regions of
interest (ROIs).26,27
Statistical analysis
Sample distribution was analyzed using the Kolmogor-
oveSmirnov and Levene tests. Non-categorical variables
were examined with Fisher’s exact test. For between-group
comparisons, the ANOVA test was used for variables with
normal distribution, with subsequent Tukey’s. Data wereow chart.
Figure 2 Circuit of lung inhalation scintigraphy.
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Chicago, IL, USA). The confidence level was set at 95% for
all tests.
The primary outcome variable was pulmonary deposition
in the ROIs with secondary outcomes changes in spirometric
variables and IC.Results
Thirty-two of the 56 patients screened participated in the
study: six were allocated to Group 1, six to Group 2, eleven
to Group 3 and nine to Group 4 (Figure 1).
Anthropometric characteristics, cardiopulmonary pa-
rameters, and baseline spirometry were similar for all
groups. However, a higher frequency of male patients was
observed in groups 1 and 2 (p Z 0.01) (Table 1).Pulmonary function test and inspiratory capacity
All groups responded to bronchodilators, but only group 1
showed a greater post-intervention increase in predicted
FEV1 % p Z 0.04 (Figure 3) and IC p Z 0.03 (Figure 3)
compared to the other Groups. We observed no significant
changes between post-intervention groups in other vari-
ables measured in spirometry (FVC, PEF, FEF 25e75% and
FEV1/FVC %).Lung inhalation scintigraphy
Analyzing the number of counts of particles deposited in the
total area of the right lung, there was greater deposition in
group 1 (482511  215291.4) and 2 (577599  129876.3)
compared to group 3 (332952  96603.03, p Z 0.02 and
p < 0.01 respectively). When compared to group 4, the dif-
ferences in deposition (409526  169419.3) was not
significant.
When evaluating the ROI in the vertical gradient we
observed higher deposition in the middle third and lower
third in groups 1 (p Z 0.02) and 2 (p Z 0.01) compared to
group 3. In the horizontal gradient, a higher deposition in
the central region in groups 1 (p Z 0.03) and 2 (p Z 0.02)
compared to group 3 and intermediate region of group 2
compared to group 3. No statistical difference wasobserved when evaluating peripheral region between the
groups (Figures 4 and 5).
Discussion
PFT response
Nebulization of bronchodilators administered with heliox
and PEP resulted in a greater increase in FEV1 % and IC than
aerosol administration with oxygen and PEP or either heliox
or oxygen alone.
The increase in IC could be explained by the physical
characteristics of heliox, which allows the formation of a
less turbulent airflow, thereby generating more flow and
time during expiration, leading to a reduction in dynamic
hyperinflation and increase in IC. On the other hand, the
use of PEP prevents airway collapse during expiration, de-
creases expiratory resistance, prolongs expiratory time and
reduces the intrinsic positive end expiratory pressure
(PEEPi),8 promoting an increase in IC.
A significant increase in FEV1 was observed in the
heliox þ PEP group, which did not occur in other groups.
Our findings can be correlated with those of Tsai et al.28
who assessed 54 stable asthmatic patients before and
after nebulization with bronchodilators associated with
PEPP and observed improvement with respect to FEV1, PEF,
FVC, as well as improvement in mucociliary clearance. Our
findings corroborate the results of a previous by Branda˜o
et al.,29 where 59 asthmatic patients were evaluated in the
emergency room and significant improvement in pulmonary
function were found when heliox was associated with
another factor, in this study, the posture.
The use of nebulization with b2-agonists and PEP has
been studied by a number of authors,7,8,11 showing
improvement in pulmonary function in asthmatic patients.
Christensen et al.7,8 assessed the influence of nebulized b2-
agonists with or without PEP in asthmatic patients in terms
of improved PEF and observed a significant increase when
they were combined, corroborating our findings.
Our results are similar to those of Christensen et al.7,8
and Tsai et al.28 when they observed an improvement in
pulmonary function associating PEP to another factor, in
this case heliox, not observing the same behavior when
compared to groups without PEP. Heliox alone has no
bronchodilating properties, despite its physical properties
such as low density and high viscosity in relation to oxygen,
which promotes the formation of less turbulent transitional
flow. As for PEP, it tends to splint the airways open during
expiration, shifting the points of equal pressure centrally,
possibly allowing greater retention of the drug in more
distal airways, optimizing bronchodilation in patients with
expiratory flow limitation.
Deposition and distribution
The ROI in horizontal and vertical gradient, was greater
deposition of particles in the middle and lower third and in
central and intermediate regions respectively in the groups
associated with PEP. No differences were noted between
the groups using heliox and oxygen with PEP. Probably, the
presence of PEP resulted in greater total deposition of
particles. Studies that evaluate the deposition of radiation
Table 1 Characteristics of the sample and spirometric values baseline.
Variables Groups p-value
Heliox þ PEEP O2 þ PEEP Heliox O2
Age (years) 40.17  11.37 51.67  10.42 49.18  5.56 46.78  11.37 0.190a
Gender 4M/2F 2M/4F 2M/9F 0M/9F 0.019b
BMI (Kg/m2) 26.11  6.81 26.17  3.27 27.90  4.42 25.95  5.34 0.807a
HR (bpm) 72.17  7.73 79  8.46 83.82  13.03 80  10.82 0.235a
RR (ipm) 13.33  3.5 17  3.46 18.09  3.75 16.22  3.38 0.091a
SPO2 (%) 97  0.89 97  1.26 97  1.18 97.67  0.70 0.456a
IC (L) 2.35  0.68 2.17  0.22 1.86  0.27 1.82  0.28 0.054a
FEV1 (% pred) 56.50  14.77 51.63  4.58 51.05  11.66 56.55  10.87 0.624a
FVC (% pred) 73.16  19.40 66.73  15.03 68.97  16.02 72.66  10.40 0.838a
PEF (% pred) 43.60  10.06 36.26  14.29 34.08  12.84 40.55  14.74 0.531a
FEF25e75% (% pred) 33.66  12.42 38.05  4.74 32.45  9.58 35.22  14.73 0.794a
FEV1/FVC (% pred) 73.50  9.11 80.01  12.91 75.69  10.59 78.11  11.14 0.731a
Values in Mean  SD.
BMI Z body mass index, HR Z heart rate, RR Z respiratory rate; SpO2 Z oxygen saturation. Heliox Z helium 80/oxigeˆnio 20,
O2Z Oxigeˆnio, PEEPZ positive end expiratory pressure; IC Z inspiratory capacity, FEV1 % predZ percentage of predicted for forced
expiratory volume in 1 s, FVC % pred Z percentage of predicted forced vital capacity, PEF % pred Z percentage of predicted for peak
expiratory flow, FEF25%e75% predZ percentage of predicted for forced expiratory flow between 25 and 75%, FEV1/FVC % predZ percent
predicted for the ratio of forced expiratory volume in 1 s and forced vital capacity.
a ANOVA.
b Fisher Exact Test.
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conducted in our laboratory, comparing radioaerosol
deposition with oxygen associated with non-invasive
ventilation using two pressure levels in healthy subjects,
showed no increase in radioaerosol deposition when
compared to nebulization without pressure support.11
Dolovich et al.14 assessed the deposition of radiation ac-
tivity form aerosol in patients with stable chronic bronchitisFigure 3 Predict (%) FEV1 and inspiratory capacity.compared use of the same nebulizer with Intermittent
Positive Pressure Breathing (IPPB) and breathing sponta-
neously reporting no increase in peripheral deposition of
aerosol with IPPB, but a greater particle impaction in the
upper airway and lower deposition to the lung compared to
nebulizer alone.
Contrary to the findings of Franc¸a et al.11 and
Dolovoch et al.,14 our findings show a greater deposition in
the lung bases in transverse direction associated with PEP,
independent of the gas used. This difference may be
attributed to different ways to deliver positive pressure and
the population studied, the studies by Franc¸a et al.11 and
Dolovoch et al.14 use bi-level ventilation and IPPB and
evaluated healthy subjects and patients with stable chronic
bronchitis respectively. As with Faraoux et al.,30 the
increased deposition found in our study possibly occurred
because PEP promotes airway dilation, providing access for
greater deposition of the inhaled drug and preventing the
collapse of unstable airways during expiration as occurs in
asthma and COPD. This improvement may occur by
increasing collateral ventilation providing better airflow to
lung periphery.
We observed a higher index of lung deposition in the
middle and lower third of the lung compared to the upper
third, and greater deposition was found in the central and
intermediate regions when compared to peripheral regions,
showing little to no impact on proximal airways in the
longitudinal section in groups with PEP. Moreover, an
irregular deposition pattern was observed in scintigraphic
images in some patients, since bronchopulmonary
obstruction may affect variable pulmonary segments. In
lungs regions with mild to severe obstruction, of the pres-
ence of transitional and turbulent flow seems to favor
deposition by impaction, concentrating the radiation ac-
tivity in hot spots close to areas of obstruction which could
explain the greater central deposition.
Figure 4 Number of counts in upper, middle and lower
regions.
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tradictions our findings and those of Anderson et al.,4
Darquenne and Prinsk2 and Bandi et al.31 In the study per-
formed by Anderson et al.,4 patients were evaluated at
different times for the retention of radionuclides within
48 h after inhalation, patients being their own control. In
our study, patients were assessed immediately after inha-
lation and until 1 h and 20 min after. In our study, the use of
a nebulizer designed for use in nuclear medicine studies
may be producing smaller particles than standard clinical
jet nebulizers and these smaller particles are less affected
by reduced turbulence with use of heliox. Another meth-
odological difference lies in the fact that all patients
included in our study were instructed to discontinue their
medication, such as short or long duration corticosteroids
and bronchodilators, 12 h before the experiment. In the
study carried out by Anderson et al.,4 no mention is made
regarding drug discontinuation. In the study by Bandi
et al.31 the subjects were evaluated twice and used as their
own control and analysis for deposition differed from that
used in this study.
On the other hand, Darquenne and Prinsk2 conducted a
study in healthy subjects and observed that ventilation
distribution depends primarily on gravity. However, in
asthmatics, it depends on the difference of inspiratory flow
as well as the level of obstruction.
Published studies have evaluated deposition of aerosol
carried by heliox. Piva et al.,5,18 in two randomized
controlled studies in children with severe distal airwayFigure 5 Number of counts in central, intermediary and
periphery.obstruction, assessed radioaerosol distribution using heliox
or oxygen as nebulization vehicles in pulmonary scintig-
raphy. Better deposition and distribution was reported in
both studies with heliox when compared to oxygen, and
these benefits became more evident in the presence of
peripheral airway obstruction.
This is the first study that links PEP with heliox in stable
asthmatic patients. In this group, bronchodilator nebuliza-
tion and heliox associated with PEP provided significant
improvement in pulmonary function. Drug deposition was
greater in the middle third and lower portions of the lungs,
regardless of type of carrier gas used with PEP. In evalu-
ating IC, groups with PEP showed higher values irrespective
of aerosol spray used, demonstrating that the use of PEEP in
nebulization was preponderant in improving pulmonary
function and IC in the subjects studied.
Few randomized controlled studies have evaluated the
benefits of aerosol therapy associated with PEP and heliox
in asthmatics between episodes.
In asthmatics, different degrees of airway obstruction
promote heterogeneous drug deposition during nebuliza-
tion. Deposition is greatest in less affected areas and in
central airways, thereby compromising the benefits of
aerosol therapy in these patients. The administration of
aerosol with PEP appears to improve the distribution of
aerosol in these patients.Limitations
The present investigation was performed in stable moder-
ate to severe asthmatics. It was not possible to provide this
same level of analysis with patients during exacerbation of
their asthma in the emergency department. Consequently,
it remains unclear whether the studied interventions would
have similar benefits in treatment of patients presenting to
the emergency department during exacerbation.
In this study it was not possible for the test in order to
identify allergens in atopic individuals as well as performing
the measurement of exhaled nitric oxide important data for
characterization of asthma.Clinical implications
Our findings demonstrate that administration of aerosol
with PEP (with either heliox or oxygen) improves distribu-
tion of aerosol, while the combination of PEP and Heliox
improves clinical response in moderate to severe stable
asthmatics. While administration of bronchodilator aerosols
with heliox have been reported in treatment of severe
asthma in the emergency room and acute care setting,
reports evaluating use of positive airway pressure in these
patients is less common prior to institution of ventilatory
support. Application of aerosol with EPAP PEP or CPAP with
Heliox in spontaneously breathing patients may have a
beneficial role in treatment, in both the acute and ambu-
latory environments. Thus, the use of heliox with PEP was
easily tolerated and may be useful as an early intervention
for asthmatics at early signs of exacerbation. Further
studies will be required to determine the role of combined
Heliox with PEP in the emergency department.
1184 L. Alcoforado et al.Conclusion
In moderate to severe asthmatics, administration of inhaled
bronchodilators with 10 cm H2O of PEP with Heliox showed
greater improvement in pulmonary function than use of
heliox alone. Further studies in the comparing administra-
tion of inhaled bronchodilators with various forms of posi-
tive airway pressure (PEP, EPAP, CPAP and PEEP) with Heliox
to determine their impact on clinical outcomes should be
encouraged.
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